Marshall Wace, LLP Ascendis Pharma A/S Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Marshall Wace, LLP holds 221,075 shares of ASND stock, worth $30.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

221,075

Previous 30,289 629.89%

Holding current value

$30.4 Million

Previous $4.13 Million 699.39%

% of portfolio

0.04%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $21.6 Million - $29.3 Million	190,786 Added 629.89%	221,075 $33 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $630,169 - $799,852	5,205 Added 20.75%	30,289 $4.13 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $3.1 Million - $4 Million	25,084 New	25,084 $3.79 Million
Q1 2023 May 15, 2023	BUY	$104.9 - $126.78 $514,010 - $621,222	4,900 Added 4.74%	108,326 $11.6 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $15.5 Million - $20.5 Million	-155,449 Reduced 60.05%	103,426 $12.6 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $16.1 Million - $21.2 Million	192,159 Added 288.03%	258,875 $26.7 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $8.06 Million - $12.1 Million	-103,195 Reduced 60.73%	66,716 $6.2 Million
Q1 2022 May 16, 2022	SELL	$102.18 - $135.75 $9.01 Million - $12 Million	-88,159 Reduced 34.16%	169,911 $19.9 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $31.1 Million - $41.5 Million	244,605 Added 1816.6%	258,070 $34.7 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $1.52 Million - $2.38 Million	13,465 New	13,465 $2.15 Million
Q2 2020 Aug 13, 2020	SELL	$110.87 - $156.01 $2.36 Million - $3.31 Million	-21,246 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $1.87 Million - $2.8 Million	19,311 Added 997.98%	21,246 $2.39 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $73,342 - $111,574	-802 Reduced 29.3%	1,935 $269,000
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $262,204 - $325,429	2,737 New	2,737 $263,000
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $3.1 Million - $3.82 Million	-28,948 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$62.15 - $129.99 $678,740 - $1.42 Million	10,921 Added 60.58%	28,948 $3.41 Million
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $650,281 - $821,339	11,789 Added 188.99%	18,027 $1.13 Million
Q3 2018 Nov 14, 2018	SELL	$63.77 - $76.28 $352,010 - $421,065	-5,520 Reduced 46.95%	6,238 $442,000
Q2 2018 Aug 14, 2018	SELL	$58.55 - $73.92 $26,933 - $34,003	-460 Reduced 3.76%	11,758 $782,000
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $476,257 - $831,312	12,218 New	12,218 $799,000

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.66B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Ascendis Pharma A/S Transaction History